PARI Pharma's Altera Delivers Gilead Sciences, Inc. (GILD)'s Cayston in Head-to-Head Study With Tobramycin Inhalation Solution
6/21/2010 11:08:20 AM
More...
|
PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA
2/11/2010 10:29:56 AM
More...
|
PARI Pharma's Altera Delivers Gilead Sciences, Inc. (GILD)'s Cayston, Approved by European Commission to Treat Cystic Fibrosis
9/24/2009 8:45:06 AM
More...
|
Mpex Pharmaceuticals, Inc. Reports Positive Phase II Results with Aeroquin, Delivered by PARI Pharma's eFlow Technology
9/15/2009 7:59:58 AM
More...
|
PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
6/3/2009 8:24:14 AM
More...
|
PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS
5/21/2009 10:48:34 AM
More...
|
PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward
5/8/2009 11:28:44 AM
More...
|
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
11/10/2008 11:55:17 AM
More...
|
PARI Pharma Unveils Closed System Using eFlow Technology at Medical Plastics Conference
10/7/2008 9:22:11 AM
More...
|
PARI Pharma's eFlow Delivers Alnylam Pharmaceuticals (ALNY) RNAi Therapeutic in Phase II Study
4/17/2008 10:27:04 AM
More...
|
|